Journal of Clinical Oncology

Reply to: “Beyond 1 Month: A Broader Look at the ROBOMET Trial Results” and “ROBOMET Revisited: Is Stereotactic Body Radiotherapy Truly Effective for Painful Bone Metastases?”

C Carole Mercier (Iridium Kankernetwerk, Antwerpen, Belgium) C Charlotte Billiet (Carole Mercier, MD, and Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Piet Ost, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Katrien Vandecasteele, MD, PhD, Department of Human Structure and Repair, Ghent University, Ghent, Belgium, Department of Radiation Oncology, University Hospital Ghent, Gent, Belgium; Geert De Kerf, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium; Michaël Claessens, PhD, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Peter Vermeulen, MD, PhD, Translational Cancer Research Unit (TCRU)—GZA Ziekenhuizen, Wilrijk, Antwerp, Belgium; Luc Dirix, MD, PhD, Departme...) P Piet Ost K Katrien Vandecasteele (Carole Mercier, MD, and Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Piet Ost, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Katrien Vandecasteele, MD, PhD, Department of Human Structure and Repair, Ghent University, Ghent, Belgium, Department of Radiation Oncology, University Hospital Ghent, Gent, Belgium; Geert De Kerf, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium; Michaël Claessens, PhD, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Peter Vermeulen, MD, PhD, Translational Cancer Research Unit (TCRU)—GZA Ziekenhuizen, Wilrijk, Antwerp, Belgium; Luc Dirix, MD, PhD, Departme...) G Geert De Kerf (Carole Mercier, MD, and Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Piet Ost, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Katrien Vandecasteele, MD, PhD, Department of Human Structure and Repair, Ghent University, Ghent, Belgium, Department of Radiation Oncology, University Hospital Ghent, Gent, Belgium; Geert De Kerf, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium; Michaël Claessens, PhD, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Peter Vermeulen, MD, PhD, Translational Cancer Research Unit (TCRU)—GZA Ziekenhuizen, Wilrijk, Antwerp, Belgium; Luc Dirix, MD, PhD, Departme...) M Michaël Claessens (Carole Mercier, MD, and Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Piet Ost, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Katrien Vandecasteele, MD, PhD, Department of Human Structure and Repair, Ghent University, Ghent, Belgium, Department of Radiation Oncology, University Hospital Ghent, Gent, Belgium; Geert De Kerf, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium; Michaël Claessens, PhD, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Peter Vermeulen, MD, PhD, Translational Cancer Research Unit (TCRU)—GZA Ziekenhuizen, Wilrijk, Antwerp, Belgium; Luc Dirix, MD, PhD, Departme...) P Peter Vermeulen L Luc Dirix (Carole Mercier, MD, and Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Piet Ost, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Katrien Vandecasteele, MD, PhD, Department of Human Structure and Repair, Ghent University, Ghent, Belgium, Department of Radiation Oncology, University Hospital Ghent, Gent, Belgium; Geert De Kerf, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium; Michaël Claessens, PhD, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Peter Vermeulen, MD, PhD, Translational Cancer Research Unit (TCRU)—GZA Ziekenhuizen, Wilrijk, Antwerp, Belgium; Luc Dirix, MD, PhD, Departme...) Y Yolande Lievens (Carole Mercier, MD, and Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Piet Ost, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Katrien Vandecasteele, MD, PhD, Department of Human Structure and Repair, Ghent University, Ghent, Belgium, Department of Radiation Oncology, University Hospital Ghent, Gent, Belgium; Geert De Kerf, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium; Michaël Claessens, PhD, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Peter Vermeulen, MD, PhD, Translational Cancer Research Unit (TCRU)—GZA Ziekenhuizen, Wilrijk, Antwerp, Belgium; Luc Dirix, MD, PhD, Departme...) D Dirk Verellen (Carole Mercier, MD, and Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Piet Ost, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Katrien Vandecasteele, MD, PhD, Department of Human Structure and Repair, Ghent University, Ghent, Belgium, Department of Radiation Oncology, University Hospital Ghent, Gent, Belgium; Geert De Kerf, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium; Michaël Claessens, PhD, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Peter Vermeulen, MD, PhD, Translational Cancer Research Unit (TCRU)—GZA Ziekenhuizen, Wilrijk, Antwerp, Belgium; Luc Dirix, MD, PhD, Departme...) P Piet Dirix (Iridium Network, Wilrijk, Belgium)
View Original
APA MLA Chicago BibTeX RIS

Article Details

Volume / Issue Vol. 43, Issue 31
Published November 01, 2025
Pages 3424-3425
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins
ISSN: 0732-183X Health Sciences

Authors (11)

C

Carole Mercier

Iridium Kankernetwerk, Antwerpen, Belgium

C

Charlotte Billiet

Carole Mercier, MD, and Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Piet Ost, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Katrien Vandecasteele, MD, PhD, Department of Human Structure and Repair, Ghent University, Ghent, Belgium, Department of Radiation Oncology, University Hospital Ghent, Gent, Belgium; Geert De Kerf, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium; Michaël Claessens, PhD, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Peter Vermeulen, MD, PhD, Translational Cancer Research Unit (TCRU)—GZA Ziekenhuizen, Wilrijk, Antwerp, Belgium; Luc Dirix, MD, PhD, Departme...

P

Piet Ost

K

Katrien Vandecasteele

Carole Mercier, MD, and Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Piet Ost, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Katrien Vandecasteele, MD, PhD, Department of Human Structure and Repair, Ghent University, Ghent, Belgium, Department of Radiation Oncology, University Hospital Ghent, Gent, Belgium; Geert De Kerf, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium; Michaël Claessens, PhD, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Peter Vermeulen, MD, PhD, Translational Cancer Research Unit (TCRU)—GZA Ziekenhuizen, Wilrijk, Antwerp, Belgium; Luc Dirix, MD, PhD, Departme...

G

Geert De Kerf

Carole Mercier, MD, and Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Piet Ost, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Katrien Vandecasteele, MD, PhD, Department of Human Structure and Repair, Ghent University, Ghent, Belgium, Department of Radiation Oncology, University Hospital Ghent, Gent, Belgium; Geert De Kerf, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium; Michaël Claessens, PhD, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Peter Vermeulen, MD, PhD, Translational Cancer Research Unit (TCRU)—GZA Ziekenhuizen, Wilrijk, Antwerp, Belgium; Luc Dirix, MD, PhD, Departme...

M

Michaël Claessens

Carole Mercier, MD, and Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Piet Ost, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Katrien Vandecasteele, MD, PhD, Department of Human Structure and Repair, Ghent University, Ghent, Belgium, Department of Radiation Oncology, University Hospital Ghent, Gent, Belgium; Geert De Kerf, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium; Michaël Claessens, PhD, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Peter Vermeulen, MD, PhD, Translational Cancer Research Unit (TCRU)—GZA Ziekenhuizen, Wilrijk, Antwerp, Belgium; Luc Dirix, MD, PhD, Departme...

P

Peter Vermeulen

L

Luc Dirix

Carole Mercier, MD, and Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Piet Ost, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Katrien Vandecasteele, MD, PhD, Department of Human Structure and Repair, Ghent University, Ghent, Belgium, Department of Radiation Oncology, University Hospital Ghent, Gent, Belgium; Geert De Kerf, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium; Michaël Claessens, PhD, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Peter Vermeulen, MD, PhD, Translational Cancer Research Unit (TCRU)—GZA Ziekenhuizen, Wilrijk, Antwerp, Belgium; Luc Dirix, MD, PhD, Departme...

Y

Yolande Lievens

Carole Mercier, MD, and Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Piet Ost, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Katrien Vandecasteele, MD, PhD, Department of Human Structure and Repair, Ghent University, Ghent, Belgium, Department of Radiation Oncology, University Hospital Ghent, Gent, Belgium; Geert De Kerf, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium; Michaël Claessens, PhD, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Peter Vermeulen, MD, PhD, Translational Cancer Research Unit (TCRU)—GZA Ziekenhuizen, Wilrijk, Antwerp, Belgium; Luc Dirix, MD, PhD, Departme...

D

Dirk Verellen

Carole Mercier, MD, and Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Piet Ost, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Katrien Vandecasteele, MD, PhD, Department of Human Structure and Repair, Ghent University, Ghent, Belgium, Department of Radiation Oncology, University Hospital Ghent, Gent, Belgium; Geert De Kerf, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium; Michaël Claessens, PhD, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Peter Vermeulen, MD, PhD, Translational Cancer Research Unit (TCRU)—GZA Ziekenhuizen, Wilrijk, Antwerp, Belgium; Luc Dirix, MD, PhD, Departme...

P

Piet Dirix

Iridium Network, Wilrijk, Belgium

Related Articles from this Journal

Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Ismaela Anna Vascotto, Filippo Antonica et al. Aug 2026 10.1200/jco-26-00658

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Samer A. Srour, Jad Chahoud et al. Aug 2026 10.1200/jco-26-00388

Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection

Risako Komata, Kenju Ando et al. Aug 2026 10.1200/jco-26-00140

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

Ghayas C. Issa, Branko Cuglievan et al. Aug 2026 10.1200/jco-26-01743

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Irbaz Bin Riaz, R. Bryan Rumble et al. Aug 2026 10.1200/jco-26-01001